|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM31732036X |
| 003 |
DE-627 |
| 005 |
20240725232234.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202004385
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1481.xml
|
| 035 |
|
|
|a (DE-627)NLM31732036X
|
| 035 |
|
|
|a (NLM)33164250
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shao, Dan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 24.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chemotherapy causes off-target toxicity and is often ineffective against solid tumors. Targeted and on-demand release of chemotherapeutics remains a challenge. Here, cancer-cell-membrane-coated mesoporous organosilica nanoparticles (MONs) containing X-ray- and reactive oxygen species (ROS)-responsive diselenide bonds for controlled release of doxorubicin (DOX) at tumor sites are developed. DOX-loaded MONs coated with 4T1 breast cancer cell membranes (CMMON@DOX) show greater accumulation at tumor sites and prolonged blood circulation time versus an uncoated control in mice bearing 4T1 orthotopic mammary tumors. Under low-dose X-ray radiation, the DOX-loaded MONs exhibit carrier degradation-controlled release via cleavage of diselenide bonds, resulting in DOX-mediated immunogenic cell death at the tumor site. Combination with a PD-L1 checkpoint blockade further enhances inhibition of tumor growth and metastasis with low systemic toxicity. Together, the findings show the promise of these biomimetic, radiation-responsive diselenide-bond-bridged MONs in chemo-immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a X-ray radiation responsivity
|
| 650 |
|
4 |
|a biodegradable mesoporous organosilica nanoparticles
|
| 650 |
|
4 |
|a biomimetic
|
| 650 |
|
4 |
|a chemo-immunotherapy
|
| 650 |
|
4 |
|a diselenide bonds
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 650 |
|
7 |
|a Organosilicon Compounds
|2 NLM
|
| 650 |
|
7 |
|a Organoselenium Compounds
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Fangman
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Xiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Hanze
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Chao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tu, Zhaoxu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Zheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chang, Zhimin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Junna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Tianyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leong, Kam W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Wen-Fei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 50 vom: 01. Dez., Seite e2004385
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:50
|g day:01
|g month:12
|g pages:e2004385
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202004385
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2020
|e 50
|b 01
|c 12
|h e2004385
|